Agnese Carmela Latorre

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Drug Therapy 37%
3. eribulin 30%
4. Capecitabine 30%
5. Interleukin-2 29%
6. Vinorelbine 29%
7. Machine Learning 21%
8. Therapeutics 21%
9. Sentinel Lymph Node 20%
10. Paclitaxel 19%
11. lonidamine 18%
12. Trastuzumab 17%
13. Taxoids 17%
14. liposomal doxorubicin 17%
15. exemestane 16%
16. Neoplasms 15%
17. Anthracyclines 14%
18. Mitoxantrone 14%
19. gemcitabine 13%
20. Observational Studies 13%
21. Ovarian Neoplasms 12%
22. Elderly 12%
23. Clinical Trials 12%
24. Tubulin 11%
25. Doxorubicin 11%
26. Platinum 11%
27. Cisplatin 11%
28. taxane 11%
29. Demography 10%
30. Lymph Nodes 10%
31. Prospective Studies 10%
32. Geriatrics 10%
33. Survival 10%
34. Progression-Free Survival 10%
35. Quality of Life 9%
36. Neutropenia 9%
37. lenvatinib 9%
38. Geriatric Assessment 8%
39. Clinical Decision Support Systems 8%
40. Maximum Tolerated Dose 8%
41. pertuzumab 8%
42. human ERBB2 protein 8%
43. Randomized Controlled Trials 8%
44. Progesterone Receptors 8%
45. Amifostine 8%
46. Melanoma 7%
47. Anastrozole 7%
48. Epirubicin 7%
49. TP protocol 7%
50. Lapatinib 7%